Ignacio Melero Bermejo

89PUBLICATIONS
459CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (89)

|Aug 06, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

|Aug 04, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

|Jul 20, 2026
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

|Jul 10, 2026
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|Jun 08, 2026
Engineering and Improving Anti-CTLA-4 Checkpoint Inhibitors.

Pageof 15

Frequent Collaborators

26 joint publications

Pedro Berraondo

14 joint publications

Álvaro Teijeira

13 joint publications

Maite Alvarez

12 joint publications

Iñaki Eguren-Santamaria